Invasive ductal carcinoma is the most common type of breast cancer, accounting for about 80% of all breast cancer diagnoses. It starts in the cells lining the milk ducts and breaks through into the surrounding breast tissue, which is what makes it “invasive.” With an estimated 321,910 new cases of female breast cancer expected in the U.S. in 2026 alone, understanding the different types and how they behave can help you make sense of a diagnosis or screening result.
Invasive Ductal Carcinoma: The 80%
Invasive ductal carcinoma, sometimes called “invasive carcinoma of no special type,” begins in the milk ducts and then grows into the fatty and connective tissue surrounding them. From there, it has the potential to spread to lymph nodes and eventually to other parts of the body. That progression involves cancer cells breaking away from the original tumor, entering the blood or lymphatic system, and establishing new growths at distant sites.
Because it’s so dominant in the statistics, invasive ductal carcinoma is also the most studied and the most straightforward to detect. Mammography picks it up with a sensitivity ranging from 63% to 98%, depending on breast density. It typically forms a distinct mass or lump that shows up clearly on imaging, which is one reason routine screening catches it relatively well.
Invasive Lobular Carcinoma: The Second Most Common
Invasive lobular carcinoma is the runner-up, making up 10% to 15% of all new breast cancer diagnoses. Instead of starting in the ducts, it begins in the lobules, the small glands that produce milk. What sets it apart is how it grows. Lobular cancer cells lack a protein that normally makes cells stick together. Without that adhesion, the cells spread in thin, single-file lines through the breast tissue rather than clumping into a solid mass.
This diffuse growth pattern creates a real problem for detection. Up to 30% of lobular cancers are invisible on mammograms, and when they are visible, their size is underestimated in up to 70% of cases. Mammographic sensitivity for lobular carcinoma ranges from just 34% to 92%, and in women with dense breast tissue, that sensitivity drops to roughly 8% to 11%. Newer imaging techniques like 3D mammography (tomosynthesis) improve detection, but lobular cancer remains more likely to be diagnosed at a larger size or later stage simply because it’s harder to find.
DCIS: The Most Common Non-Invasive Type
Not all breast cancers have broken through the duct wall. Ductal carcinoma in situ (DCIS) is a non-invasive or “pre-invasive” breast cancer that stays contained inside the milk ducts. It now accounts for 20% to 25% of all newly diagnosed breast cancers in the U.S. and represents 17% to 34% of cancers found through mammography screening.
DCIS itself hasn’t spread and isn’t immediately life-threatening. But it carries a meaningful risk of becoming invasive over time, which is why treatment is typically recommended rather than observation alone. Think of it as a warning stage: the abnormal cells are there, but they haven’t yet gained the ability to invade surrounding tissue.
Molecular Subtypes: A Different Way to Classify
Beyond where the cancer starts (ducts vs. lobules), breast cancers are also classified by the molecular receptors on their cells. This classification matters because it determines which treatments will work. Among more than 320,000 women diagnosed between 2010 and 2016 in a large U.S. study, the breakdown looked like this:
- Luminal A (72.6%): hormone receptor-positive, tends to grow slowly, and generally has the best prognosis. This is by far the most common molecular subtype.
- Luminal B (11.2%): also hormone receptor-positive but grows faster than luminal A and may need more aggressive treatment.
- Triple-negative (11.3%): lacks hormone receptors and the HER2 protein, which means it doesn’t respond to hormone therapies or HER2-targeted drugs. It tends to be more aggressive and has fewer treatment options.
- HER2-enriched (4.8%): driven by overproduction of the HER2 protein. Targeted therapies have dramatically improved outcomes for this subtype over the past two decades.
A single tumor has both a histological type (ductal, lobular) and a molecular subtype. So someone might be diagnosed with invasive ductal carcinoma that is luminal A, meaning it started in the ducts and is hormone receptor-positive. Both classifications together guide treatment decisions.
How Risk Varies by Race and Ethnicity
The overall incidence of breast cancer is highest among White women (127.7 per 100,000) and Black women (125.1 per 100,000), with lower rates in Asian/Pacific Islander, Hispanic, and American Indian/Alaska Native women. But incidence alone doesn’t tell the full story.
Black women have a death rate of 29.2 per 100,000, compared to 20.6 per 100,000 for White women, despite similar incidence rates. Part of this disparity comes from biology: triple-negative breast cancer, the most aggressive molecular subtype, occurs in Black women at roughly twice the rate seen in White women. Tumors in Black and Hispanic women are also more likely to be larger at diagnosis, lack hormone receptors, and show features associated with faster growth.
Age patterns differ too. Before age 45, Black women have higher breast cancer rates than White women. Between ages 60 and 84, that relationship reverses, with White women showing notably higher incidence. Environmental factors also play a role. Asian American women born in the U.S. have breast cancer risk comparable to White women, while recent immigrants from Asia show significantly lower rates, pointing to the influence of lifestyle and environmental exposures over time.
What This Means for Screening
Because invasive ductal carcinoma forms distinct masses, standard mammography catches most cases effectively. But if you have dense breast tissue, detection rates drop for all types, and lobular cancer becomes especially easy to miss. Women with dense breasts may benefit from supplemental screening with MRI or ultrasound, particularly if they have other risk factors.
The rise of DCIS diagnoses over recent decades is largely a result of improved mammography. More sensitive screening finds more early-stage abnormalities, which is a double-edged sword: it catches cancers before they become invasive, but it also identifies some that might never have caused harm. This is an active area of debate in oncology, particularly around how aggressively DCIS should be treated.
Regardless of type, breast cancers caught early, before they’ve spread beyond the breast, have significantly better outcomes. The specific type and molecular subtype then determine what treatment looks like, from hormone-blocking pills taken for years to targeted therapies to chemotherapy. Knowing which type you’re dealing with is the first step toward understanding what comes next.